Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None202520242023202220212020 November 30, 2023 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology November 3, 2023 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update October 23, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations September 20, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ September 5, 2023 Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 3, 2023 Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update May 15, 2023 Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ May 4, 2023 Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update May 2, 2023 Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations April 28, 2023 Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development March 8, 2023 Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 1, 2023 Protara Therapeutics to Participate in Upcoming Investor Conferences Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page › Last page » Displaying 25 - 36 of 94 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None202520242023202220212020 November 30, 2023 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology November 3, 2023 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update October 23, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations September 20, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ September 5, 2023 Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 3, 2023 Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update May 15, 2023 Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ May 4, 2023 Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update May 2, 2023 Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations April 28, 2023 Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development March 8, 2023 Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 1, 2023 Protara Therapeutics to Participate in Upcoming Investor Conferences Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page › Last page » Displaying 25 - 36 of 94
November 30, 2023 Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
November 3, 2023 Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
October 23, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
September 20, 2023 Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
September 5, 2023 Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 3, 2023 Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
May 15, 2023 Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
May 2, 2023 Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
April 28, 2023 Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical Development
March 8, 2023 Protara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
